Cause-specific mortality following radical prostatectomy

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 1, 2012, Pages 106-110

  Shikanov, S ^a   Kocherginsky, M ^a   Shalhav, A L ^a   Eggener, S E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

mortality; population cohort; radical prostatectomy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER STAGING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RACE; RISK FACTOR; SURGICAL RISK;

ADULT; AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84857035985     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.55     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869-875.
3. Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer 1998; 83: 1180-1188. (Pubitemid 28419072)
4. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Nat Cancer Inst 2000; 92: 613-621. (Pubitemid 30321303)
5. Cancer Statistics Datasets & Software Publications Information for Cancer Registrars, Homepage. .
6. Surveillance Research Program, NCI. Cancer Statistics Datasets & Software Publications Information for Cancer Registrars. index.html.
7. Surveillance Research Program, NCI. SEER Program: Camparative Staging Guide for Cancer. manuals/historic/comp-stage1.1pdf.
8. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
9. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007; 13: 559-565. (Pubitemid 46225362)
10. Marubini E, M GV. Analysing Survival Data from Clinical Trials and Observational Studies. Wiley: Chichester, 1995.
11. Blanchard CM, Courneya KS, Stein K. Cancer survivors0 adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society0s SCS-II. J Clin Onc 2008; 26: 2198-2204.
12. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden Follow-up Study. J Nat Cancer Inst 2010; 102: 950-958.
13. Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 2007; 177: 932-936. (Pubitemid 46223573)
14. Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Onc 2008; 26: 4027-4034.
15. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011; 59: 88-95.
16. Bill-Axelson A, Holmberg L, Filen F, RuutuM, Garmo H, Busch C, Nordling S et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Nat Cancer Inst 2008; 100: 1144-1154.
17. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Onc 2006; 24: 4448-4456. (Pubitemid 46630983)
18. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493-1500. (Pubitemid 47463063)
19. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: Are death certificates valid? J Nat Cancer Inst 2001; 93: 1822-1823. (Pubitemid 33150456)